Top Markets
#1 Islamic Coin Islamic Coin +155.97%
#2 Siren Siren +37.56%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.25%
#4 Verus Coin Verus Coin +22.40%
#5 Cysic Cysic +19.84%
#6 Arowana Arowana +19.40%
#7 OpenEden OpenEden +17.23%
#8 Perle Perle +14.78%
#9 Ocean Protocol Ocean Protocol +13.13%
#10 RedStone RedStone +12.61%
Coin of the day
Islamic Coin Islamic Coin
Beállítások
Nyelv
MAGYAR
Pénznem
USD
Téma
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc.

VTGN
Helyezés a részvények között #31928
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity... VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Részvényárfolyam
$0.2619
Utolsó szinkronizálás: 2026-08-17
Piaci kapitalizáció
$11.62M
Változás (1 nap)
-2.13%
Változás (1 év)
-92.30%
Ország
US
Kereskedés VistaGen Therapeutics, Inc. (VTGN)

Kategória

Healthcare
VistaGen Therapeutics, Inc. (VTGN) részvényárfolyamának története
Legmagasabb napi záróár: $0.27 ekkor: 2026-08-01

Legalacsonyabb napi záróár: $1.53K ekkor: 2011-06-01
VistaGen Therapeutics, Inc. részvényárfolyamának története 2011 és 2026 között
Éves részvényárfolyam teljesítmény
Év Teljesítmény
2026 (TTM) -36.45%
2025 2.70%
2024 -46.68%
2023 39.81%
2022 -93.85%
2021 73.02%
2020 65.87%
2019 -58.43%
2018 30.09%
2017 -67.26%
2016 -39.96%
2015 -31.19%
2014 31.23%
2013 -53.04%
2012 -75.74%
2011 0.00%
Hasonló cégek vagy versenytársak részvényárai
Vállalat Részvényár Változás 1év% Ország
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $515.58 32.24%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $992.01 50.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $111.31 -36.83%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $736.38 6.95%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.06K -7.04%
KR